Press-release for stocks listed in the nasdaq exchange

Prices are updated after-hours

exchanges : Nasdaq source : Investors.biomarin.com

save search

BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA
Published: 2024-01-03 (Crawled : 13:00) - investors.biomarin.com
BMRN | News S | $90.48 -0.43% -0.43% 1.3M

Health Technology

| -7.34% | O: 0.96% H: 0.0% C: -2.33%
conference

BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany
Published: 2023-11-28 (Crawled : 14:00) - investors.biomarin.com
BMRN | News S | $90.48 -0.43% -0.43% 1.3M

Health Technology

| 2.54% | O: -0.21% H: 0.12% C: -0.74%
roctavian health germany insurance agreement

BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer
Published: 2023-11-01 (Crawled : 20:00) - investors.biomarin.com
BMRN | News S | $90.48 -0.43% -0.43% 1.3M

Health Technology

| 8.14% | O: -3.58% H: 0.93% C: -1.64%

BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
Published: 2023-11-01 (Crawled : 20:00) - investors.biomarin.com
SNY | News | $46.125 0.71% 0.7% 3.7M

Health Technology

| 0.5% | O: 3.0% H: 0.0% C: 0.0%
BMRN | News S | $90.48 -0.43% -0.43% 1.3M

Health Technology

| 8.14% | O: -3.58% H: 0.93% C: -1.64%
year total growth

BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
Published: 2023-09-21 (Crawled : 14:30) - investors.biomarin.com
BMRN | News S | $90.48 -0.43% -0.43% 1.3M

Health Technology

| 2.79% | O: -0.68% H: 0.52% C: -1.72%
voxzogo children achondroplasia meeting growth

BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th
Published: 2023-09-06 (Crawled : 13:00) - investors.biomarin.com
BMRN | News S | $90.48 -0.43% -0.43% 1.3M

Health Technology

| 0.12% | O: -0.43% H: 1.25% C: 0.72%
day pipeline

BioMarin to Participate in Three Upcoming Investor Conferences
Published: 2023-09-05 (Crawled : 12:30) - investors.biomarin.com
MS | News | $90.08 1.06% -0.28% 9.5M

Finance

| 5.34% | O: 0.01% H: 0.0% C: 0.0%
BMRN | News S | $90.48 -0.43% -0.43% 1.3M

Health Technology

| -2.34% | O: -0.59% H: 0.14% C: -1.88%

BioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ET
Published: 2023-07-12 (Crawled : 13:20) - investors.biomarin.com
BMRN | News S | $90.48 -0.43% -0.43% 1.3M

Health Technology

| 6.57% | O: 0.12% H: 0.88% C: -0.13%
conference financial results

U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A
Published: 2023-06-29 (Crawled : 19:00) - investors.biomarin.com
BMRN | News S | $90.48 -0.43% -0.43% 1.3M

Health Technology

| 2.16% | O: 1.2% H: 1.97% C: -3.69%
drug food therapy

BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress
Published: 2023-06-22 (Crawled : 12:00) - investors.biomarin.com
BMRN | News S | $90.48 -0.43% -0.43% 1.3M

Health Technology

| -5.7% | O: -0.32% H: 0.18% C: -0.44%
international program trial therapy

BioMarin to Participate in Bank of America 2023 Health Care Conference
Published: 2023-05-04 (Crawled : 20:00) - investors.biomarin.com
BMRN | News S | $90.48 -0.43% -0.43% 1.3M

Health Technology

| -4.82% | O: 0.36% H: 1.41% C: 0.88%
america conference health care

BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues
Published: 2023-04-26 (Crawled : 20:00) - investors.biomarin.com
SNY | News | $46.125 0.71% 0.7% 3.7M

Health Technology

| -20.62% | O: -3.56% H: 0.0% C: 0.0%
BMRN | News S | $90.48 -0.43% -0.43% 1.3M

Health Technology

| -2.31% | O: -1.0% H: 1.46% C: 0.41%
total growth

BioMarin to Host First Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, April 26, at 4:30pm ET
Published: 2023-04-13 (Crawled : 13:00) - investors.biomarin.com
BMRN | News S | $90.48 -0.43% -0.43% 1.3M

Health Technology

| -7.26% | O: -0.66% H: 1.71% C: 1.06%
conference financial results

BioMarin to Share Updated Data at 2023 American College of Medical Genetics and Genomics (ACMG) Meeting Demonstrating Commitment to Understanding Long-Term Benefit of VOXZOGO® in Children with Achondroplasia
Published: 2023-03-14 (Crawled : 12:00) - investors.biomarin.com
BMRN | News S | $90.48 -0.43% -0.43% 1.3M

Health Technology

| 0.92% | O: 1.61% H: 0.11% C: -1.33%
voxzogo meeting children medical genomics achondroplasia

FDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO® (vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 5
Published: 2023-03-07 (Crawled : 22:00) - investors.biomarin.com
BMRN | News S | $90.48 -0.43% -0.43% 1.3M

Health Technology

| -2.75% | O: 0.12% H: 1.14% C: 0.83%
voxzogo fda drug children application achondroplasia injection

BioMarin to Participate in Three Investor Conferences in March
Published: 2023-03-02 (Crawled : 14:00) - investors.biomarin.com
BMRN | News S | $90.48 -0.43% -0.43% 1.3M

Health Technology

| -10.04% | O: -0.59% H: 0.4% C: -0.27%